BioSpace
SEPTEMBER 17, 2023
After evidence of “overwhelming reduction” in bleeding compared to Bayer and J&J’s Xarelto, Anthos Therapeutics has ended its Phase II atrial fibrillation study for abelacimab ahead of schedule.
ProRelix Research
SEPTEMBER 17, 2023
The rising prevalence of ophthalmology disorders such as dry eye disease (DED) and vision-related issues is largely related to the increasing use of mobile phones, tablet screens, and laptops. Since […] The post Ophthalmology disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
SEPTEMBER 17, 2023
The first annual BioTechX USA, held in Santa Clara in September, bridged the communication gap by bringing together life sciences leaders in all areas of the industry.
JAMA Internal Medicine
SEPTEMBER 17, 2023
This case report presents the electrocardiogram findings of a patient in their 50s with syncope and palpitation and amaurosis followed by loss of consciousness for several minutes without preceding position change, cough, chest pain, or shortness of breath.
BioSpace
SEPTEMBER 17, 2023
Following a regulatory victory for Jemperli in endometrial cancer last month, GSK continued its oncology winning streak with an FDA approval for momelotinib in adult myelofibrosis patients with anemia.
JAMA Internal Medicine
SEPTEMBER 17, 2023
This cross-sectional study examines how well a hospital’s online prices for vaginal childbirth and brain magnetic resonance imaging correlate with their prices provided via telephone.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
FDA Law Blog
SEPTEMBER 17, 2023
By Philip Won & Véronique Li, Senior Medical Device Regulation Expert — Over the last three and a half years, meetings with FDA were conducted virtually. During this time, CDRH moved from Webex to Zoom and gained experience with the virtual platform. Now, in addition to engaging with FDA via Zoom, medical device sponsors can once again engage in in-person meetings with the Agency.
BioSpace
SEPTEMBER 17, 2023
The legal battle over the Inflation Reduction Act’s price negotiation program moved to federal court in Ohio with the Department of Justice and U.S. Chamber of Commerce sparring about the law.
Drug Patent Watch
SEPTEMBER 17, 2023
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharma companies have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
SEPTEMBER 17, 2023
The FDA will finish September with three action dates and one of the year’s most highly-anticipated advisory committee meetings.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
SEPTEMBER 17, 2023
From reversing overdose to blocking cravings, the biopharma industry is looking at a range of possible solutions to addiction.
BioSpace
SEPTEMBER 17, 2023
The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.
Expert insights. Personalized for you.
127 
Let's personalize your content